Kerastem Licenses China and ASEAN Hair Growth Markets to MyungMoon Bio; Company Expands Upon Existing Partnership in South Korea
Tuesday, May 14, 2019 8:30 AM
SOLANA BEACH, CA and SEOUL, SOUTH KOREA / ACCESSWIRE / May 14, 2019 / Kerastem, the leader in the development and commercialization of regenerative medicine-based approaches to hair growth, and MyungMoon Bio Co. Ltd, a leading healthcare company bringing innovative regenerative therapies to market, announce the expansion of their existing commercial partnership to bring Kerastem's novel hair growth cell therapy to China and ASEAN Member States.
Click here to view the full press release, including media-ready images, downloadable resources, and more.
Kerastem is a wholly owned subsidiary of Bimini Technologies. The Bimini portfolio includes Puregraft (www.puregraft.com), the world's leading fat transfer solution. In 15 minutes or less, Puregraft products provide surgeons with purified fat for reinjection and are used in hospitals and clinics around the world. The existing Puregraft customer base are ideal prospects for Kerastem's hair growth cell therapy.
About MyungMoon Bio Co. Ltd
MyungMoon Bio is a leading manufacturer and distributor of medical device and pharmaceutical products in South Korea. The company develops medicines and medical supplies for the treatment of incurable disease and introduces excellent therapeutic products to the Korean market through strong partnership with global healthcare providers. MyungMoon Bio aspires to be the most respected company to improve the quality of patients' lives.
Corporate and Media Contact